Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)

NCT06405633 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.

NCT NCT06405633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06405633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
Lead sponsor
Wave Life Sciences USA, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 19, 2024
Completion date
September 30, 2026
Enrollment
24 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency